InsidersTradesSigma
Total declarations
Company
▲ Purchases (4 ops.)
▼ Sales (0 ops.)
Insider track record
Board DirectorDisclosed buys
4
Disclosed sells
0
T+90 hit rate
18%
T+90 mean return
-19.2%
Across 11 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the detailed record of transactions filed by Scott Byron C, Director. Insider active across 1 company, notably ACCURAY INC. In total, 15 reports have been logged. Breakdown: 4 buys · 0 sell. Total volume traded: €147k. Activity tracked since 18 August 2021. The latest transaction was filed on 21 November 2025 (Retenue fiscale). Regulator: SEC (Form 4). All data is openly available.
Declarations15 total
56,603 shares0Common StockSEC:0001214659-25-017246:0
22,642 shares@ US$1.053.2% of flowCommon StockSEC:0001214659-25-017246:1
22,642 shares@ US$1.986.5% of flowCommon StockSEC:0001214659-24-018864:0
56,603 shares0Common StockSEC:0001214659-23-016011:0
23,622 shares@ US$2.478.6% of flowCommon StockSEC:0001214659-23-015158:0
59,055 shares0Common StockSEC:0001214659-22-014662:0
12,474 shares@ US$2.334.4% of flowCommon StockSEC:0001214659-22-014166:0
31,185 shares@ US$4.810.41% mcap27.1% of flowCommon StockSEC:0001214659-21-012599:0
31,185 shares@ US$4.8120.9% of flowCommon StockSEC:0001214659-21-012599
8,152 shares@ US$5.326.1% of flowCommon StockSEC:0001214659-21-012259
8,152 shares@ US$5.320.12% mcap7.9% of flowCommon StockSEC:0001214659-21-012259:0
9,000 shares@ US$5.44970.13% mcap8.7% of flowCommon StockSEC:0001214659-21-011354:0
Ideal exit: 5 Aug 2022 (T+270)
9,000 shares@ US$5.44976.7% of flowCommon StockSEC:0001214659-21-011354
Ideal exit: 5 Aug 2022 (T+270)
10,000 shares@ US$3.650.097% mcap6.4% of flowCommon StockSEC:0001214659-21-008819:0
Ideal exit: 15 May 2022 (T+270)
10,000 shares@ US$3.654.9% of flowCommon StockSEC:0001214659-21-008819
Ideal exit: 15 May 2022 (T+270)
15 of 15 declarations
About Scott Byron C
Byron C. Scott is a Director at ACCURAY INC. As a board member, he participates in the governance of the company and strategic decision-making. His expertise in the medical technology sector helps ACCURAY develop innovative solutions to improve patient care.
